Abstracts tagged "cancer and rheumatoid arthritis (RA)"

Abstract Number: 492 • 2018 ACR/ARHP Annual Meeting
All Site Cancers and Lymphoma Incidence in US Veterans with Rheumatoid Arthritis 2001-2015
Namrata Singh¹, Yubo Gao², Bryant R. England³, Punyasha Roul⁴, Elizabeth Field⁵, Joshua Baker⁶, Brian Sauer⁷, Ted R. Mikuls⁸, Grant W. Cannon⁹, Jeffrey R. Curtis¹⁰, Mary Vaughan-Sarrazin² and Charles Lynch¹¹, ¹Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Iowa City VA, Iowa City, IA, ⁶Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT, ⁸Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Epidemiology, University of Iowa, Iowa City, IA
Background/Purpose: Patients with rheumatoid arthritis (RA) have a modest increased risk of overall cancer and of lymphoma. The purpose of our study was to report…
Abstract Number: 943 • 2018 ACR/ARHP Annual Meeting
Risk of Prostate Cancer in US Veterans with Rheumatoid Arthritis
Kaitlyn Brittan¹, Punyasha Roul², Joshua Baker³, Brian Sauer⁴, Namrata Singh⁵, Harlan Sayles², Grant W. Cannon⁶, Ted R. Mikuls⁷ and Bryant R. England⁸, ¹University of Nebraska Medical Center & VA Nebraska-Western IA Health Care System, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, ⁶Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁷VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are at a small, but significantly increased risk of cancer compared with the general population. This risk varies by…
Abstract Number: 1962 • 2017 ACR/ARHP Annual Meeting
Rates of Malignancy Associated with Anti-TNF Agents and Subsequent Biologic Use after Malignancy Using U.S. SEER Registry Data
Huifeng Yun¹, Fenglong Xie², Shuo Yang², Lang Chen¹ and Jeffrey R. Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (DMARDs) have been widely used for treatment of rheumatoid arthritis (RA) in United States. However, it is not clear whether…
Abstract Number: 2404 • 2017 ACR/ARHP Annual Meeting
Use of Dmards after the Diagnosis of Cancers in Patients with RA
Young Bin Joo, Yune-Jung Park, Ki-Jo Kim and Kyung-Su Park, Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South)
Background/Purpose: Although there are many studies about the association of disease-modifying anti-rheumatic drugs (DMARDs) with cancers in patients with rheumatoid arthritis (RA), there are few…
Abstract Number: 2546 • 2016 ACR/ARHP Annual Meeting
Utilization of Biologic Therapy in Patients with Rheumatoid Arthritis and Cancer
Natalia V. Zamora¹, Harish Siddhanamatha², Andrea Barbo³, Jean Tayar⁴, Heather Lin⁵ and Maria Suarez-Almazor⁶, ¹Section of Rheumatology and Clinical Immunology, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴Department of Gentic Internal Medicine-AT & EC, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵Biostatistics, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁶Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: Biologic therapy for rheumatoid arthritis (RA) downregulates the immune response. Tumoral immunity is an important host mechanism against cancer progression, and for this reason,…
Abstract Number: 3066 • 2016 ACR/ARHP Annual Meeting
Risk of Incident Cancer with Biologic and Tofacitinib Therapy in Rheumatoid Arthritis
Bryant R. England¹, Sofia Pedro², Ted R Mikuls³ and Kaleb Michaud^2,4, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The immune system recognizes, controls, and eliminates tumors through a process of immunosurveillance. In RA, where there is an increased incidence of lymphoma and…
Abstract Number: 1560 • 2015 ACR/ARHP Annual Meeting
The Effect of Anti Estrogen Therapy (AET) on Rheumatoid Arthritis
Bassam Alhaddad¹, Amrita Kaur Bath², Bassem Zraik³, Mohamed Alalwani⁴ and Stanley P Ballou¹, ¹Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²Internal medicine, Fairview Hospital- Cleveland Cinic, Cleveland, OH, ³Internal Medicine, Fairview Hospital- Cleveland Clinic, cleveland, OH, ⁴Hospital Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: The well-known positive effect of pregnancy on improving Rheumatoid Arthritis (RA) disease activity suggests that hormonal changes may play a role in disease pathogenesis…
Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting
The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication
Layla Saliba¹, Guillaume Moulis², Malak Aboutaam³, Grégory Pugnet², Vanessa Rousseau¹, Leila Chebane¹, Nadine Petitpain⁴, Bernadette Baldin⁵, Jean-Louis Montastruc¹ and Haleh Bagheri¹, ¹Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, ²Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, ⁴Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, ⁵Nice University Hospital, Pharmacovigilance Regional Center, Nice, France
Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].